In vivo gene delivery to immune cells.
Curr Opin Biotechnol
; 88: 103169, 2024 Aug.
Article
em En
| MEDLINE
| ID: mdl-38972172
ABSTRACT
Immune cell therapies are an emerging class of living drugs that rely on the delivery of therapeutic transgenes to enhance, modulate, or restore cell function, such as those that encode for tumor-targeting receptors or replacement proteins. However, many cellular immunotherapies are autologous treatments that are limited by high manufacturing costs, typical vein-to-vein time of 3-4 weeks, and severe immune-related adverse effects. To address these issues, different classes of gene delivery vehicles are being developed to target specific immune cell subsets in vivo to address the limitations of ex vivo manufacturing, modulate therapeutic responses in situ, and reduce on- and off-target toxicity. The success of in vivo gene delivery to immune cells - which is being tested at the preclinical and clinical stages of development for the treatment of cancer, infectious diseases, and autoimmunity - is paramount for the democratization of cellular immunotherapies.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Terapia Genética
/
Técnicas de Transferência de Genes
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Curr Opin Biotechnol
Assunto da revista:
BIOTECNOLOGIA
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Estados Unidos